Skip navigation

Goldenseal


What is it?

Goldenseal is an herb. The dried root is used to make medicine.

Goldenseal is used for many conditions, but so far, there isn’t enough scientific evidence to determine whether or not it is effective for any of them.

We do know that goldenseal isn’t effective for its most famous use, masking illegal drugs in the urine. Despite rumors to the contrary, goldenseal won’t cause false-negative results for marijuana, cocaine, amphetamines or numerous other illegal drugs. Interestingly, the idea of using goldenseal to alter drug screen results came from the novel Stringtown on the Pike, by the pharmacist John Uri Lloyd. However, in this book, goldenseal caused a false-positive for strychnine poisoning, not illegal drugs.

Goldenseal is also used for the common cold and other upper respiratory tract infections, as well as stuffy nose and hay fever. Some people use goldenseal for digestive disorders including stomach pain and swelling (gastritis), peptic ulcers, colitis, diarrhea, constipation, hemorrhoids, and intestinal gas.

Goldenseal is used for urinary tract infections (UTIs), internal bleeding, bleeding after childbirth, liver disorders, cancer, chronic fatigue syndrome (CFS), jaundice, gonorrhea, fever, pneumonia, malaria, whooping cough, and an eating disorder called anorexia.

Women use goldenseal for vaginal pain and swelling and menstrual period problems.

Goldenseal is applied to the skin for rashes, ulcers, wound infections, itching, eczema, acne, dandruff, ringworm, herpes blisters, and cold sores. It is used as a mouthwash for sore gums and mouth.

Some people use goldenseal as an eyewash for eye inflammation and eye infections called conjunctivitis, or “pink eye.”

Goldenseal is used in the ears for ringing, earache, and deafness.

Goldenseal is commonly found in the deep woods from Vermont to Arkansas and received its name from the golden-yellow scars on the base of the stem. When the stem is broken, the scar resembles a gold wax letter seal.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for GOLDENSEAL are as follows:

Possibly ineffective for...

  • Masking illegal drugs in urine tests. Goldenseal is often promoted to mask illicit drugs in the urine, but taking goldenseal by mouth doesn’t seem to cause a false-negative result on drug tests for amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidine, and tetrahydrocannabinol (THC). Drinking one gallon of water with goldenseal doesn’t increase the number of false negatives over water alone.

Insufficient evidence to rate effectiveness for...

  • Urinary tract infections (UTIs).
  • Hemorrhoids.
  • Stomach upset.
  • Loss of appetite (anorexia).
  • Stomach ulcers.
  • Colitis.
  • Menstrual irregularities.
  • Chronic fatigue syndrome (CFS).
  • Conjunctivitis.
  • Nasal congestion.
  • Hay fever.
  • Other conditions.
More evidence is needed to rate goldenseal for these uses.

How does it work?

Return to top
Goldenseal contains the chemical berberine, which might have effects against bacteria and fungi. For example, it can prevent the bacteria Escherichia coli (E. coli) from binding to urinary tract walls. Berberine also has properties that can lower blood pressure and improve irregular heartbeats. In addition, early research suggests that berberine can lower blood sugar and “bad” low-density lipoprotein (LDL) cholesterol.

Many of the important chemicals in goldenseal are poorly absorbed when taken by mouth and might not reach the concentrations needed to have significant effects in humans. So, it is unknown whether goldenseal has the same benefits as berberine.

Are there safety concerns?

Return to top
Goldenseal is POSSIBLY SAFE when used as a single dose. There is not enough reliable information to know if goldenseal is safe for long-term use.

Don't use goldenseal in newborn babies. It is LIKELY UNSAFE for them. It might cause brain damage (kernicterus).

Special precautions & warnings:

Pregnancy and breast-feeding: Using goldenseal during pregnancy or breast-feeding is LIKELY UNSAFE for the infant. A hazardous chemical in goldenseal can cross the placenta and can also find its way into breast milk. Brain damage (kernicterus) has developed in newborn infants exposed to goldenseal. Do not use goldenseal during pregnancy or breast-feeding.

Are there interactions with medications?

Return to top

Moderate

Be cautious with this combination.

Cyclosporine (Neoral, Sandimmune)
The body breaks down cyclosporine (Neoral, Sandimmune) to get rid of it. Goldenseal might decrease how fast the body breaks down cyclosporine (Neoral, Sandimmune). This might cause there to be too much cyclosporine (Neoral, Sandimmune) in the body and could potentially cause side effects.

Digoxin (Lanoxin)
Taking goldenseal with digoxin (Lanoxin) might cause a very slight increase in digoxin (Lanoxin) levels in the body. But this does not seem to be an important interaction.

Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates)
Some medications are changed and broken down by the liver. Goldenseal might decrease how quickly the liver breaks down some medications. Taking goldenseal along with some medications that are changed by the liver can increase the effects and side effects of your medication. Before taking goldenseal, talk to your healthcare provider if you take any medications that are changed by the liver.

Some medications that are changed by the liver include amitriptyline (Elavil), clozapine (Clozaril), codeine, desipramine (Norpramin), donepezil (Aricept), fentanyl (Duragesic), flecainide (Tambocor), fluoxetine (Prozac), meperidine (Demerol), methadone (Dolophine), metoprolol (Lopressor, Toprol XL), olanzapine (Zyprexa), ondansetron (Zofran), tramadol (Ultram), trazodone (Desyrel), and others.

Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates)
Some medications are changed and broken down by the liver. Goldenseal might decrease how quickly the liver breaks down some medications. Taking goldenseal along with some medications that are broken down by the liver can increase the effects and side effects of some medications. Before taking goldenseal, talk to your healthcare provider if you are taking any medications that are changed by the liver.

Some medications changed by the liver include lovastatin (Mevacor), clarithromycin (Biaxin), indinavir (Crixivan), sildenafil (Viagra), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), triazolam (Halcion), and many others.

Medications moved by pumps in cells (P-Glycoprotein Substrates)
Some medications are moved by pumps in cells. Goldenseal might make these pumps less active and increase the amount of some medications that get absorbed by the body. This might increase the amount of some medications in the body, which could lead to more side effects. But there is not enough information to know if this is a big concern.

Some medications that are moved by these pumps include etoposide, paclitaxel, vinblastine, vincristine, vindesine, ketoconazole, itraconazole, amprenavir, indinavir, nelfinavir, saquinavir, cimetidine, ranitidine, diltiazem, verapamil, corticosteroids, erythromycin, cisapride (Propulsid), fexofenadine (Allegra), cyclosporine, loperamide (Imodium), quinidine, and others.

Are there interactions with herbs and supplements?

Return to top
There are no known interactions with herbs and supplements.

Are there interactions with foods?

Return to top
There are no known interactions with foods.

What dose is used?

Return to top
The appropriate dose of goldenseal depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for goldenseal. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

Other names

Return to top
Chinese Goldenseal, Eye Balm, Eye Root, Fard Inolien, Framboise de Terre, Goldenroot, Goldsiegel, Ground Raspberry, Hydraste, Hydraste du Canada, Hydrastis canadensis, Indian Dye, Indian Plant, Indian Tumeric, Jaundice Root, Orange Root, Racine à la Jaunisse, Racine Orange, Sceau D'Or, Sello de Oro, Turmeric Root, Warnera, Wild Curcuma, Yellow Indian Paint, Yellow Paint, Yellow Puccoon, Yellow Root.

Methodology

Return to top
To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.methodology (http://www.nlm.nih.gov/medlineplus/druginfo/natural/methodology.html).

References

Return to top
To see all references for the Goldenseal page, please go to http://www.nlm.nih.gov/medlineplus/druginfo/natural/943.html.

  1. Winek CL, Elzein EO, Wahba WW, and et al. Interference of herbal drinks with urinalysis for drugs of abuse. Journal of Analytical Toxicology 1993;17:246-247.
  2. Bolle P, Cometa MF, Palmery M, and et al. Response of rabbit detrusor muscle to total extract and major alkaloids of Hydrastis canadensis. Phytotherapy Research 1998;12:S86-S88.
  3. Sabir M, Akhter MH, and Bhide NK. Further studies on pharmacology of berberine. Ind J Physiol Pharmac 1978;22:9-23.
  4. Vik-Mo, H, Faria DB, Cheung W, and et al. Beneficial effects of berberine on left ventricular function in dogs with heart failure. Clinical Research 1983;31:224a.
  5. Rehman J, Dillow JM, Carter SM, and et al. Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Immunology Letters 1999;68:391-395.
  6. Cometa MF, Abdel-Haq H, and Palmery M. Spasmolytic activities of Hydrastis canadensis L. on rat uterus and guinea-pig trachea. Phytotherapy Research 1998;12(suppl 1):S83-S85.
  7. Tice R. Goldenseal (Hydrastis canadensis L.) and two of its constituent alkaloids: berberine [2086-83-1] and Hydrastine [118-08-1]. Review of toxicological Literature. 1997;i-vi, 1-52.
  8. Khin-Maung U, Myo-Khin, Nyunt-Nyunt-Wai, and et al. Clinical trial of high-dose berberine and tetracycline in cholera. J Diarrhoeal Dis Res 1987;5:184-187.
  9. Palmery M, Leone M, Pimpinella G, and et al. Effects of Hydrastis canadensis L. and the two major alkaloids berberine and hydrastine on rabbit aorta. Pharmacological Research 1993;27(suppl 1):73-74.
  10. Swanston-Flatt SK, Day C, Bailey CJ, and et al. Evaluation of traditional plant treatments for diabetes: studies in streptozotocin diabetic mice. Acta Diabetol.Lat 1989;26:51-55.
  1. Ivanovska N and Philipov S. Study on the anti-inflammatory action of Berberis vulgaris root extract, alkaloid fractions and pure alkaloids. Int J Immunopharmac 1996;18:553-561.
  2. Ribeiro LG, Bowker BL, Maroko PR, and et al. Beneficial effects of berberine on early mortality after experimental coronary artery occlusion in rats. Circulation 1982;66(II):56.
  3. Betz JM, Miller LJ, Musser SM, and et al. Differentiation between goldenseal (Hydrastis canadensis L.) and possible adulterants by LC/MCS of the alkaloids. FDA 1997 Science Forum :Abstract A1.
  4. Sabir M, Mahajan VM, Mohapatra LN, and et al. Experimental study of the antitrachoma action of berberine. Indian J Med Res 1976;64:1160-1167. View abstract.
  5. Lahiri S and Dutta NK. Berberine and chloramphenicol in the treatment of cholera and severe diarrhoea. Journal of the Indian Medical Association 1967;48:1-11. View abstract.
  6. Mikkelsen SL and Ash KO. Adulterants causing false negatives in illicit drug testing. Clin Chem 1988;34:2333-2336. View abstract.
  7. Gurley, B. J., Fifer, E. K., and Gardner, Z. Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med. 2012;78:1490-1514. View abstract.
  8. Cecil, C. E., Davis, J. M., Cech, N. B., and Laster, S. M. Inhibition of H1N1 influenza A virus growth and induction of inflammatory mediators by the isoquinoline alkaloid berberine and extracts of goldenseal (Hydrastis canadensis). Int.Immunopharmacol. 2011;11:1706-1714. View abstract.
  9. National Toxicology Program. Toxicology and carcinogenesis studies of goldenseal root powder (Hydrastis Canadensis) in F344/N rats and B6C3F1 mice (feed studies). Natl.Toxicol.Program.Tech.Rep.Ser. 2010;:1-188. View abstract.
  10. Kim, J. B., Yu, J. H., Ko, E., Lee, K. W., Song, A. K., Park, S. Y., Shin, I., Han, W., and Noh, D. Y. The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine. 2010;17:436-440. View abstract.
  11. Brown, J. C. and Jiang, X. Prevalence of antibiotic-resistant bacteria in herbal products. J.Food Prot. 2008;71:1486-1490. View abstract.
  12. Serafim, T. L., Oliveira, P. J., Sardao, V. A., Perkins, E., Parke, D., and Holy, J. Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line. Cancer Chemother.Pharmacol. 2008;61:1007-1018. View abstract.
  13. Bhowmick, S. K., Hundley, O. T., and Rettig, K. R. Severe hypernatremia and hyperosmolality exacerbated by an herbal preparation in a patient with diabetic ketoacidosis. Clin Pediatr (Phila) 2007;46:831-834. View abstract.
  14. Yao, M., Ritchie, H. E., and Brown-Woodman, P. D. A reproductive screening test of goldenseal. Birth Defects Res B Dev Reprod Toxicol 2005;74:399-404. View abstract.
  15. Pan, G. Y., Huang, Z. J., Wang, G. J., Fawcett, J. P., Liu, X. D., Zhao, X. C., Sun, J. G., and Xie, Y. Y. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med 2003;69:632-636. View abstract.
  16. Lee, C. J., Lee, J. H., Seok, J. H., Hur, G. M., Park, Y. C., Seol, I. C., and Kim, Y. H. Effects of baicalein, berberine, curcumin and hesperidin on mucin release from airway goblet cells. Planta Med. 2003;69:523-526. View abstract.
  17. Abdel-Haq, H., Cometa, M. F., Palmery, M., Leone, M. G., Silvestrini, B., and Saso, L. Relaxant effects of Hydrastis canadensis L. and its major alkaloids on guinea pig isolated trachea. Pharmacol Toxicol. 2000;87:218-222. View abstract.
  18. Zadoyan, G. and Fuhr, U. Phenotyping studies to assess the effects of phytopharmaceuticals on in vivo activity of main human cytochrome p450 enzymes. Planta Med. 2012;78:1428-1457. View abstract.
  19. Shi, S. and Klotz, U. Drug interactions with herbal medicines. Clin Pharmacokinet. 2-1-2012;51:77-104. View abstract.
  20. Sevior, D. K., Hokkanen, J., Tolonen, A., Abass, K., Tursas, L., Pelkonen, O., and Ahokas, J. T. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 2010;40:245-254. View abstract.
  21. Rabbani G. Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. Danish Medical Bulletin 1996;43:173-185.
  22. Kaneda Y, Torii M, Tanaka T, and et al. In vitro effects of berberine sulphate on the growth and structure of Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis. Annals of Tropical Medicine and Parasitology 1991;85:417-425.
  23. Hamon, NW. Goldenseal. CPJ-RPC 1990;508-510.
  24. Sharma R, Joshi CK, and Goyal RK. Berberine tannate in acute diarrhoea. Indian Pediatrics 1970;7:496-501.
  25. Dutta NK and Panse MV. Usefulness of berberine (an alkaloid from Berberis aristata) in the treatment of cholera (experimental). Indian J Med Res 1962;50:732-736.
  26. Chekalina, S. I., Umurzakova, R. Z., Saliev, K. K., and Abdurakhmanov, T. R. [Effect of berberine bisulfate on platelet hemostasis in thrombocytopenia patients]. Gematologiia i Transfuziologiia 1994;39:33-35. View abstract.
  27. Babbar, O. P., Chhatwal, V. K., Ray, I. B., and Mehra, M. K. Effect of berberine chloride eye drops on clinically positive trachoma patients. Indian J Med Res. 1982;76 Suppl:83-88. View abstract.
  28. Mohan, M., Pant, C. R., Angra, S. K., and Mahajan, V. M. Berberine in trachoma. (A clinical trial). Indian J Ophthalmol. 1982;30:69-75. View abstract.
  29. Chun YT, Yip TT, Lau KL, and et al. A biochemical study on the hypotensive effect of berberine in rats. Gen Pharmac 1979;10:177-182. View abstract.
  30. Desai, A. B., Shah, K. M., and Shah, D. M. Berberine in treatment of diarrhoea. Indian Pediatr. 1971;8:462-465. View abstract.
  31. Khin, Maung U., Myo, Khin, Nyunt, Nyunt Wai, Aye, Kyaw, and Tin, U. Clinical trial of berberine in acute watery diarrhoea. Br.Med.J.(Clin.Res.Ed) 12-7-1985;291:1601-1605. View abstract.
  32. Hermann, R. and von, Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 2012;78:1458-1477. View abstract.
  33. Doggrell, S. A. Berberine--a novel approach to cholesterol lowering. Expert.Opin.Investig.Drugs 2005;14:683-685. View abstract.
  34. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., Wang, S., Wu, J., Wang, Y., Li, Z., Liu, J., and Jiang, J. D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344-1351. View abstract.
  35. Kuo, C. L., Chi, C. W., and Liu, T. Y. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 1-20-2004;203:127-137. View abstract.
  36. Jantova, S., Cipak, L., Cernakova, M., and Kost'alova, D. Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharm Pharmacol 2003;55:1143-1149. View abstract.
  37. Hong, Y., Hui, S. S., Chan, B. T., and Hou, J. Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. Life Sci. 4-18-2003;72:2499-2507. View abstract.
  38. Kowalewski, Z., Mrozikiewicz, A., Bobkiewicz, T., Drost, K., and Hladon, B. [Toxicity of berberine sulfate]. Acta Pol.Pharm 1975;32:113-120. View abstract.
  39. Zeng, X. and Zeng, X. Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC. Biomed Chromatogr 1999;13:442-444. View abstract.
  40. Palanisamy, A., Haller, C., and Olson, K. R. Photosensitivity reaction in a woman using an herbal supplement containing ginseng, goldenseal, and bee pollen. J Toxicol.Clin Toxicol. 2003;41:865-867. View abstract.
  41. Sun D, Courtney HS, and Beachey EH. Berberine sulfate blocks adherence of Streptococcus pyogenes to epithelial cells, fibronectin, and hexadecane. Antimicrobial Agents and Chemotherapy 1988;32:1370-1374.
  42. Palasuntheram C, Iyer KS, de Silva LB, and et al. Antibacterial activity of Coscinium fenestratum Colebr against Clostridium tetani. Ind J Med Res 1982;76(Suppl):71-76.
  43. Tai YH, Feser JF, Marnane WG, and et al. Antisecretory effects of berberine in rat ileum. Am J Physiol 1981;241:G253-G258.
  44. Zhu B and Ahrens FA. Effect of berberine on intestinal secretion mediated by Escherichia coli heat-stable enterotoxin in jejunum of pigs. Am J Vet Res 1982;43:1594-1598.
  45. Zalewski A, Krol R, and Maroko PR. Berberine, a new inotropic agent - distinction between its cardiac and peripheral responses. Clin Res 1983;31:227A.
  46. Krol R, Zalewski A, and Maroko PR. Beneficial effects of berberine, a new positive inotropic agent, on digitalis-induced ventricular arrhythmias. Circulation 1982;66(suppl 2):56.
  47. Krol R, Zalewski A, Cheung W, and et al. Additive effects of berberine and ouabain on myocardial contractility. Clin Res 1982;30:673A.
  48. Kaneda Y, Tanaka T, and Saw T. Effects of berberine, a plant alkaloid, on the growth of anaerobic protozoa in axenic culture. Tokai J Exp Clin Med 1990;15:417-423.
  49. Ghosh AK, Bhattacharyya FK, and Ghosh DK. Leishmania donovani: amastigote inhibition and mode of action of berberine. Experimental Parasitology 1985;60:404-413.
  50. Huang W, Zhang Z, and Xu Y. Study of the effects and mechanisms of berberine on slow-response action potentials. Journal of Electrocardiology 1990;23:231-234.
  51. Lewin NA, Howland MA, and Goldfrank LR. Herbal Preparations. Goldfrank's Toxicological Emergencies. Norwalk, CT: Appleton & Lange;1996.
  52. Tripathi YB and Shukla SD. Berberis artistata inhibits PAF induced aggregation of rabbit platelets. Phytotherapy Research 1996;10:628-630.
  53. Sheng WD, Jiddawi MS, Hong XQ, and et al. Treatment of chloroquine-resistant malaria using pyrimethamine in combination with berberine, tetracycline or cotrimoxazole. East African Medical Journal 1997;74:283-284.
  54. Sabir M and Bhide NK. Study of some pharmacological actions of berberine. Ind J Physiol & Pharmac 1971;15:111-132.
  55. Sharda DC. Berberine in the treatment of diarrhoea of infancy and childhood. J Indian M A 1970;54:22-24.
  56. Ksiezycka E, Cheung W, and Maroko PR. Antiarrhythmic effects of berberine on aconitine-induced ventricular and supraventricular arrhythmias. Clinical Research 1983;31:197A.
  57. Mahajan VM, Sharma A, and Rattan A. Antimycotic activity of berberine sulphate: an alkaloid from an Indian medicinal herb. Sabouraudia 1982;20:79-81.
  58. Nishino H, Kitagawa K, Fujiki H, and et al. Berberine sulfate inhibits tumor-promoting activity of teleocidin in two-stage carcinogenesis on mouse skin. Oncology 1986;43:131-134.
  59. Kumazawa Y, Itagaki A, Fukumoto M, and et al. Activation of peritoneal macrophages by berberine-type alkaloids in terms of induction of cytostatic activity. Int J Immunopharmac 1984;6:587-592.
  60. Kuo CL, Chou CC, and Yung BY. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Letters 1995;93:193-200.
  61. Liu CX, Xiao PG, and Liu GS. Studies on plant resources, pharmacology and clinical treatment with berbamine. Phytotherapy Research 1991;5:228-230.
  62. Miura N, Yamamoto M, Ueki T, and et al. Inhibition of thymocyte apoptosis by berberine. Biochemical Pharmacology 1997;53:1315-1322.
  63. Gao, C. R., Zhang, J. Q., and Huang, Q. L. [Experimental study on berberin raised insulin sensitivity in insulin resistance rat models]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 1997;17:162-164. View abstract.
  64. Peng, W. H., Hsieh, M. T., and Wu, C. R. Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. Jpn J Pharmacol 1997;74:261-266. View abstract.
  65. Ckless, K., Schlottfeldt, J. L., Pasqual, M., Moyna, P., Henriques, J. A., and Wajner, M. Inhibition of in-vitro lymphocyte transformation by the isoquinoline alkaloid berberine. J Pharm Pharmacol. 1995;47(12A):1029-1031. View abstract.
  66. Wu, J. F. and Liu, T. P. [Effects of berberine on platelet aggregation and plasma levels of TXB2 and 6-keto-PGF1 alpha in rats with reversible middle cerebral artery occlusion]. Yao Xue.Xue.Bao. 1995;30:98-102. View abstract.
  67. Yuan, J., Shen, X. Z., and Zhu, X. S. [Effect of berberine on transit time of human small intestine]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 1994;14:718-720. View abstract.
  68. Chi, C. W., Chang, Y. F., Chao, T. W., Chiang, S. H., P'eng, F. K., Lui, W. Y., and Liu, T. Y. Flowcytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. Life Sci. 1994;54:2099-2107. View abstract.
  69. Swabb, E. A., Tai, Y. H., and Jordan, L. Reversal of cholera toxin-induced secretion in rat ileum by luminal berberine. Am J Physiol 1981;241:G248-G252. View abstract.
  70. Sack, R. B. and Froehlich, J. L. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infect Immun. 1982;35:471-475. View abstract.
  71. Ghosh, A. K., Rakshit, M. M., and Ghosh, D. K. Effect of berberine chloride on Leishmania donovani. Indian J Med.Res. 1983;78:407-416. View abstract.
  72. Zhu, B. and Ahrens, F. Antisecretory effects of berberine with morphine, clonidine, L- phenylephrine, yohimbine or neostigmine in pig jejunum. Eur J Pharmacol 12-9-1983;96(1-2):11-19. View abstract.
  73. Shanbhag, S. M., Kulkarni, H. J., and Gaitonde, B. B. Pharmacological actions of berberine on the central nervous system. Jpn.J Pharmacol 1970;20:482-487. View abstract.
  74. Choudhry, V. P., Sabir, M., and Bhide, V. N. Berberine in giardiasis. Indian Pediatr. 1972;9:143-146. View abstract.
  75. Creasey, W. A. Biochemical effects of berberine. Biochem.Pharmacol. 4-1-1979;28:1081-1084. View abstract.
  76. Kulkarni, S. K., Dandiya, P. C., and Varandani, N. L. Pharmacological investigations of berberine sulphate. Jpn.J Pharmacol. 1972;22:11-16. View abstract.
  77. Chan, M. Y. The effect of berberine on bilirubin excretion in the rat. Comp Med East West 1977;5:161-168. View abstract.
  78. Saxe, T. G. Toxicity of medicinal herbal preparations. Am.Fam.Physician 1987;35:135-142. View abstract.
  79. Marin-Neto, J. A., Maciel, B. C., Secches, A. L., and Gallo, Junior L. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin.Cardiol. 1988;11:253-260. View abstract.
  80. Ni, Y. X. [Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research]. Zhong.Xi.Yi.Jie.He.Za Zhi.- Chinese Journal of Modern Developments in Traditional Medicine 1988;8:711-3, 707. View abstract.
  81. Zhang, M. F. and Shen, Y. Q. [Antidiarrheal and anti-inflammatory effects of berberine]. Zhongguo Yao Li Xue.Bao. 1989;10:174-176. View abstract.
  82. Shaffer, J. E. Inotropic and chronotropic activity of berberine on isolated guinea pig atria. J Cardiovasc Pharmacol 1985;7:307-315. View abstract.
  83. Chang, K. S., Gao, C., and Wang, L. C. Berberine-induced morphologic differentiation and down-regulation of c- Ki-ras2 protooncogene expression in human teratocarcinoma cells. Cancer Lett. 12-3-1990;55:103-108. View abstract.
  84. Zhang, R. X., Dougherty, D. V., and Rosenblum, M. L. Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors. Chin Med.J (Engl.) 1990;103:658-665. View abstract.
  85. Hui, K. K., Yu, J. L., Chan, W. F., and Tse, E. Interaction of berberine with human platelet alpha 2 adrenoceptors. Life Sci. 1991;49:315-324. View abstract.
  86. Khin, Maung U. and Nwe, Nwe Wai. Effect of berberine on enterotoxin-induced intestinal fluid accumulation in rats. J Diarrhoeal Dis Res 1992;10:201-204. View abstract.
  87. Lau, C. W., Yao, X. Q., Chen, Z. Y., Ko, W. H., and Huang, Y. Cardiovascular actions of berberine. Cardiovasc Drug Rev 2001;19:234-244. View abstract.
  88. Mitani, N., Murakami, K., Yamaura, T., Ikeda, T., and Saiki, I. Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma. Cancer Lett. 4-10-2001;165:35-42. View abstract.
  89. Krishnan, P. and Bastow, K. F. The 9-position in berberine analogs is an important determinant of DNA topoisomerase II inhibition. Anticancer Drug Des 2000;15:255-264. View abstract.
  90. Li, T. K., Bathory, E., LaVoie, E. J., Srinivasan, A. R., Olson, W. K., Sauers, R. R., Liu, L. F., and Pilch, D. S. Human topoisomerase I poisoning by protoberberines: potential roles for both drug-DNA and drug-enzyme interactions. Biochemistry 6-20-2000;39:7107-7116. View abstract.
  91. Li, H., Miyahara, T., Tezuka, Y., Namba, T., Suzuki, T., Dowaki, R., Watanabe, M., Nemoto, N., Tonami, S., Seto, H., and Kadota, S. The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. Biol Pharm Bull 1999;22:391-396. View abstract.
  92. Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessement of CYP2D6-mediated herb-drug interactions in humans: Effects of milk-thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008;52:755-63. View abstract.
  93. Gurley BJ, Swain A, Barone GW, et al. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2007;35:240-5. View abstract.
  94. Kim SH, Shin DS, Oh MN, et al. Inhibition of the bacterial surface protein anchoring transpeptidase sortase by isoquinoline alkaloids. Biosci Biotechnol Biochem 2004;68:421-4.. View abstract.
  95. Li B, Shang JC, Zhou QX. [Study of total alkaloids from rhizoma coptis chinensis on experimental gastric ulcers]. Chin J Integr Med 2005;11:217-21. View abstract.
  96. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005;77:415-26. View abstract.
  97. Ang ES, Lee ST, Gan CS, et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second-degree burns. Med Gen Med 2001;3:3. View abstract.
  98. Tsai PL, Tsai TH. Hepatobiliary excretion of berberine. Drug Metab Dispos 2004;32:405-12. . View abstract.
  99. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005;61:567-72. View abstract.
  100. Khosla PG, Neeraj VI, Gupta SK, et al. Berberine, a potential drug for trachoma. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique 1992;69:147-65. View abstract.
  101. Hsiang CY, Wu SL, Cheng SE, Ho TY. Acetaldehyde-induced interleukin-1beta and tumor necrosis factor-alpha production is inhibited by berberine through nuclear factor-kappaB signaling pathway in HepG2 cells. J Biomed Sci 2005;12:791-801. View abstract.
  102. Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001;53:763-8. . View abstract.
  103. Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003;92:173-6. View abstract.
  104. Janbaz KH, Gilani AH. Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in rodents. Fitoterapia 2000;71:25-33.. View abstract.
  105. Fukuda K, Hibiya Y, Mutoh M, et al. Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells. J Ethnopharmacol 1999;66:227-33. View abstract.
  106. Park KS, Kang KC, Kim JH, et al. Differential inhibitory effects of protoberberines on sterol and chitin biosyntheses in Candida albicans. J Antimicrob Chemother 1999;43:667-74. View abstract.
  107. Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol 2003;43:1283-8.. View abstract.
  108. Scazzocchio F, Corneta MF, Tomassini L, Palmery M. Antibacterial activity of Hydrastis canadensis extract and its major isolated alkaloids. Planta Med 2001;67:561-4. View abstract.
  109. Arinaga S, Karimine N, Takamuku K, et al. Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. Int J Immunopharmac 1992;14:535-539. View abstract.
  110. Nishino H, Kitagawa K, Fujiki H, Iwashima A. Berberine sulfate inhibits tumor-promoting activity of teleocidin in two-stage carcinogenesis on mouse skin. Oncology 1986;43:131-4. View abstract.
  111. Sun D, Courtney HS, Beachey EH. Berberine sulfate blocks adherence of Streptococcus pyogenes to epithelial cells, fibronectin, and hexadecane. Antimicrob Agents Chemother 1988;32:1370-4. View abstract.
  112. Amin AH, Subbaiah TV, Abbasi KM. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can J Microbiol 1969;15:1067-76. View abstract.
  113. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-82. View abstract.
  114. Bhide MB, Chavan SR, Dutta NK. Absorption, distribution and excretion of berberine. Indian J Med Res 1969;57:2128-31. View abstract.
  115. Winek CL, Elzein EO, Wahba WW, Feldman JA. Interference of herbal drinks with urinalysis for drugs of abuse. J Anal Toxicol 1993;17:246-7. View abstract.
  116. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate 1993;63:201-8. View abstract.
  117. Gupte S. Use of berberine in treatment of giardiasis. Am J Dis Child 1975;129:866. View abstract.
  118. Kaneda Y, Torii M, Tanaka T, Aikawa M. In vitro effects of berberine sulphate on the growth and structure of Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis. Ann Trop Med Parasitol 1991;85:417-25. View abstract.
  119. Sun D, Abraham SN, Beachey EH. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob Agents Chemother 1988;32:1274-7. View abstract.
  120. Rehman J, Dillow JM, Carter SM, et al. Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Immunol Lett 1999;68:391-5. View abstract.
  121. Rabbani GH, Butler T, Knight J, et al. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis 1987;155:979-84. View abstract.
  122. Wu AH, Forte E, Casella G, et al. CEDIA for screening drugs of abuse in urine and the effect of adulterants. J Forensic Sci 1995;40:614-8. View abstract.
  123. Cone EH, Lange R, Darwin WD. In vivo adulteration: excess fluid ingestion causes false-negative marijuana and cocaine urine test results. J Anal Toxicol 1998;22:460-73. View abstract.
  124. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  125. Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
Show more references
Show fewer references
Last reviewed - 07/15/2011




Page last updated: 08 September 2014